discoveri
antibiot
microb
earli
centuri
major
impact
societi
save
countless
live
yet
broad
rang
inhibitor
viral
pathogen
present
avail
classic
antivir
strategi
target
viral
structur
enzymat
motif
high
specif
potenti
low
side
effect
agent
howev
prone
viral
evas
select
resist
strain
identifi
novel
chemic
inhibitor
viru
infect
perform
highcont
imagebas
infect
screen
use
librari
approxim
known
bioactiv
food
drug
administr
fda
approv
small
compound
abil
inhibit
human
rhinoviru
hrv
infect
hela
cell
hrv
belong
genu
enterovirida
picornaviru
famili
picornavirus
small
nonenvelop
virus
capsid
nm
diamet
plussens
nucleotid
rna
genom
genom
encod
singl
polyprotein
proteolyt
process
infect
hrv
compris
one
hundr
known
serotyp
frequent
viral
infect
among
human
predomin
caus
common
cold
hrv
infect
pose
sever
health
risk
patient
preexist
airway
condit
includ
chronic
obstruct
pulmonari
diseas
asthma
cystic
fibrosi
may
relat
observ
hrv
limit
upper
respiratori
tract
also
infect
lower
respiratori
tract
two
receptor
group
defin
speci
b
virus
minor
group
virus
compris
twelv
member
util
lowdens
lipoprotein
receptor
ldlr
protein
cell
entri
major
group
use
intracellular
adhes
molecul
infect
typic
phdepend
requir
passag
virus
acid
endosom
compart
recent
discov
speci
c
hrv
preval
young
children
appear
use
distinct
unknown
attach
site
infect
vaccin
effect
antivir
avail
hrv
despit
fact
noninfluenza
relat
viral
respiratori
infect
predominantli
hrv
lead
econom
loss
usd
billion
per
year
us
alon
among
top
reason
prescript
antibiot
earlier
develop
small
compound
hrv
target
capsid
viral
proteas
function
exampl
pleconaril
rupintrivir
none
antivir
molecul
pass
phase
iii
clinic
trial
approv
fda
broad
human
applic
identifi
niclosamid
inhibitor
infect
niclosamid
fda
approv
antihelmint
compound
use
human
sinc
forti
year
appli
agrochem
human
therapi
well
toler
rat
acut
oral
toxic
dose
larger
gkg
bodi
weight
margin
decreas
haemoglobin
concentr
erythrocyt
count
occur
male
femal
rat
given
niclosamid
gkgday
four
week
niclosamid
origin
develop
farbenfabriken
bayer
base
observ
bithionol
potent
antihelmint
activ
later
work
hydroxylbiphenyl
led
discoveri
niclofolan
modifi
niclosamid
niclosamid
introduc
market
trade
name
bayluscid
bayer
use
decad
treat
gastrointestin
tapeworm
infect
human
anim
overview
see
niclosamid
receiv
renew
attent
due
antivir
effect
sever
acut
respiratori
syndrom
sar
viru
antianthrax
toxin
properti
antineoplast
activ
addit
niclosamid
potent
induc
autophagosom
inhibitor
wntfrizzl
pathway
suppressor
autonom
notchsignal
pathway
inhibitor
mtor
signal
addit
uncoupl
mitochondri
oxid
phosphoryl
thu
slow
cell
growth
imagebas
highcont
infect
screen
hela
cell
identifi
niclosamid
librari
known
bioactiv
compound
potent
low
micromolar
inhibitor
infect
test
efficaci
niclosamid
block
picornaviru
infect
use
panel
differ
enterovirus
compris
four
hrv
coxsackievirus
cv
found
phdepend
hrv
use
ldlr
famili
tropic
major
group
genet
group
b
sensit
niclosamid
concentr
maxim
inhibit
figur
b
figur
text
larg
phindepend
coxsacki
adenoviru
receptor
car
tropic
broadli
unaffect
valu
respect
also
reflect
therapeut
index
ti
reflect
ratio
latter
concentr
half
maxim
toxic
measur
cellular
energi
level
use
resazurin
fluorometr
assay
assess
toxic
niclosamid
toxic
clearli
separ
antivir
efficaci
least
see
figur
figur
text
toxic
profil
close
match
antivir
efficaci
herp
simplex
viru
valu
exceed
contrast
niclosamid
effect
inhibit
influenza
viru
strain
apuerto
depict
human
lung
adenocarcinoma
epitheli
cell
cell
line
fulli
permiss
influenza
viru
replic
figur
niclosamid
also
effect
antivir
nontransform
cell
includ
human
embryon
diploid
airway
cell
infect
supplementari
figur
text
howev
affect
inhibit
profil
virus
pretreat
niclosamid
min
suggest
nonviru
target
figur
text
cellular
inhibit
profil
niclosamid
close
resembl
bafilomycin
strongli
inhibit
mildli
figur
text
profil
also
similar
ammonium
chlorid
addit
experi
see
figur
text
data
shown
high
mutat
rate
quasispeci
natur
picornavirus
facilit
emerg
select
drugresist
escap
mutant
particularli
restrict
direct
viral
factor
address
issu
blind
propag
presenc
niclosamid
effect
concentr
rang
approxim
hrv
replic
cycl
observ
shift
sensit
propag
niclosamid
figur
text
known
due
low
genet
complex
inoculum
lack
spontan
mutat
passag
collect
data
show
phdepend
infect
affect
niclosamid
phindepend
infect
assess
stage
viral
life
cycl
niclosamid
act
ad
compound
post
infect
pi
hela
cell
hrv
figur
b
figur
text
result
show
addit
niclosamid
genom
releas
necessari
maxim
inhibit
hrv
infect
half
maxim
effect
min
pi
infect
unaffect
suggest
niclosamid
inhibit
earli
step
infect
presum
viru
entri
result
similar
timecours
experi
entri
inhibitor
pleconaril
bind
hrv
capsid
neutral
acid
endosom
block
vacuolar
atpas
see
figur
text
test
niclosamid
irrevers
inhibitor
pretreat
cell
compound
either
min
h
wash
cell
drugfre
medium
complet
abolish
antivir
effect
case
figur
figur
text
suggest
mode
inhibit
involv
high
affin
drug
target
irrevers
metabol
chang
cell
even
exceed
longterm
incub
better
defin
inhibit
mode
niclosamid
perform
trap
experi
temperatur
uptak
cargo
earli
endosom
allow
membran
matur
sort
earli
compart
strongli
slow
intern
h
follow
treatment
niclosamid
drug
affect
capsid
convers
use
term
capsid
convers
measur
cellular
cue
prime
viru
rna
releas
exampl
virusreceptor
interact
low
endosom
ph
capsid
convers
measur
sensit
hrv
pleconaril
bind
capsid
interfer
immedi
earli
receptor
bind
step
hrv
endosom
convers
v
ldlr
tropic
hrv
unpublish
data
data
show
readili
bypass
pleconaril
block
figur
v
ldlrtropic
contrast
remain
least
partli
pleconarilsensit
indic
get
past
step
toward
acid
compart
phdepend
convers
step
occur
shown
earlier
v
ldlrtropic
expect
inhibit
infect
phindepend
ad
h
likewis
niclosamid
block
ad
block
conclud
niclosamid
inhibit
infect
receptor
bind
transport
viru
earli
endosom
major
niclosamidesensit
virus
studi
name
hrv
influenza
viru
requir
lowph
step
infecti
entri
therefor
test
niclosamid
neutral
low
endosom
ph
measur
ratiometr
imag
acridin
orang
ao
fluoresc
figur
ao
accumul
vesicular
compart
emit
red
fluoresc
supposedli
due
quench
acid
compart
upon
treat
cell
lysosomotrop
agent
vatpas
inhibitor
emit
fluoresc
ao
shift
red
green
indic
dequench
upon
endosom
ph
neutral
ratiometr
live
cell
measur
show
niclosamid
increas
vesicular
ph
similar
figur
figur
b
text
result
confirm
lysotrack
measur
show
steep
declin
fluoresc
upon
treatment
micromolar
concentr
niclosamid
nanomolar
concentr
figur
indic
niclosamid
neutral
low
ph
endosom
compart
well
establish
endolysosom
acidif
larg
driven
vatpas
consumpt
atp
review
test
niclosamid
affect
vatpas
activ
isol
bovin
brain
clathrinco
vesicl
ccv
measur
hydrolysi
atp
product
inorgan
phosphat
pi
niclosamid
effect
atp
consumpt
vatpas
inhibitor
concanamycin
conc
complet
block
product
pi
figur
text
electron
micrograph
isol
ccv
see
figur
indic
niclosamid
inhibit
vatpas
activ
next
test
antivir
effect
niclosamid
due
block
endosom
acidif
trap
compart
h
presenc
niclosamid
incub
cell
medium
low
ph
h
follow
normal
infect
medium
without
niclosamid
h
presenc
pleconaril
inactiv
nonconvert
particl
found
addit
ph
medium
revers
inhibitori
effect
niclosamid
trap
virus
promot
infect
figur
infect
stimul
pronounc
ph
possibl
due
activ
viru
penetr
plasma
membran
similar
result
obtain
treatment
trap
viru
inhibit
revers
ph
albeit
ph
effici
ph
data
shown
notabl
treatment
cell
ph
buffer
lead
acidif
cytosol
inhibit
infect
togeth
result
indic
niclosamid
affect
low
phdepend
step
entri
process
past
compart
earli
endosom
import
passageway
varieti
virus
mildli
acid
ph
sinc
observ
niclosamid
inhibit
virus
strongli
ph
depend
also
less
ph
depend
investig
niclosamid
affect
phenotyp
earli
endosom
stain
earli
endosom
antigen
found
morpholog
alter
posit
structur
niclosamidetr
cell
specif
endosom
cluster
perinuclear
area
figur
e
perinuclear
intens
lysosom
associ
membran
protein
posit
structur
less
affect
notabl
lesser
extent
lysosomotrop
agent
chloroquin
compar
phenotyp
effect
niclosamid
figur
e
text
similar
result
also
obtain
normal
diploid
cell
indic
cell
type
independ
effect
data
shown
test
niclosamid
directli
affect
ph
within
endosom
measur
ph
isol
ccv
ao
red
fluoresc
assay
niclosamid
conca
neutral
ph
ccv
dosedepend
manner
figur
g
notabl
lower
compar
cellular
assay
seen
frequent
cell
free
assay
collect
data
indic
niclosamid
neutral
ph
acid
endosom
niclosamid
weak
acid
estim
pka
ph
molecul
deproton
form
octanolwat
distribut
coeffici
log
p
niclosamid
increas
ph
test
correl
antivir
activ
neutral
endosom
ph
perform
structureact
relationship
studi
librari
sixteen
niclosamiderel
compound
carri
differ
function
group
posit
control
includ
niclosamid
two
differ
sourc
prestwick
sigmaaldrich
found
reagent
virtual
ident
efficaci
figur
four
sixteen
niclosamiderel
compound
antivir
activ
compar
niclosamid
figur
contain
featur
stabil
proton
form
suggest
hydroxyl
group
central
amid
nh
ph
sensit
group
condens
hydroxyl
group
ethoxyphenyl
diminish
antivir
efficaci
compar
niclosamid
indic
hydroxyl
group
alon
essenti
howev
substitut
hydroxyl
proton
alkyl
group
replac
electroneg
cl
group
hydrogen
elimin
antivir
activ
true
electronwithdraw
nitro
group
replac
less
electronwithdraw
group
import
electroneg
group
benzen
ring
confirm
reduc
antivir
efficaci
confirm
antivir
activ
control
compound
phdepend
influenza
viru
lesser
extent
figur
figur
text
similar
niclosamid
antivir
activ
compound
inhibit
infect
ad
earli
phase
min
ad
post
entri
min
figur
text
weakli
inhibit
treatment
niclosamid
compound
inhibit
profil
compar
entri
inhibitor
although
slightli
affect
infect
latter
effect
like
due
pleiotrop
effect
cell
physiolog
furthermor
readili
neutral
acid
endosom
determin
ratiometr
ao
assay
lysotrack
fluoresc
analys
hela
cell
figur
figur
text
collect
studi
indic
inhibit
profil
niclosamid
relat
compound
aciddepend
virus
close
match
ph
neutral
profil
compound
explor
mode
action
niclosamid
test
protonophor
abil
niclosamid
proteinfre
unilamellar
liposom
load
dextranfitc
quench
fitc
fluoresc
liposom
load
ph
manner
similar
endosom
load
dextranfitc
upon
short
incub
niclosamid
fitcfluoresc
rapidli
dequench
half
maxim
efficaci
figur
fluoresc
dequench
similar
protonophor
dnp
dinitrophenol
cccp
carbonylcyanidmchlorophenylhydrazon
valid
assay
system
notabl
niclosamid
affect
integr
liposom
indic
laser
scatter
size
determin
electron
microscopi
neg
stain
liposom
wherea
deterg
triton
disintegr
liposom
data
suppli
direct
evid
niclosamid
act
proton
carrier
acid
vesicular
lumen
ph
neutral
cytosol
figur
next
test
combin
treatment
cell
niclosamid
addit
synergist
antivir
effect
preincub
cell
serial
dilut
niclosamid
combin
show
strong
addit
inhibit
infect
determin
singl
cell
highcont
infect
assay
figur
b
low
concentr
niclosamid
synergist
inhibit
infect
found
determin
macsynergi
ii
figur
text
synergist
effect
strong
agreement
result
full
cycl
assay
low
concentr
niclosamid
nm
alon
decreas
viru
titer
fivefold
drug
combin
figur
togeth
data
indic
host
interfer
level
endosom
acidif
two
distinct
mechan
synergist
block
viru
entri
infect
identifi
tool
human
rhinovirus
screen
librari
fdaapprov
chemic
compound
among
top
hit
infect
niclosamid
niclosamid
well
toler
human
oral
use
g
per
adult
cestocid
treatment
lead
maxim
serum
concentr
correspond
well
within
antivir
activ
concentr
rang
nontox
human
niclosamid
salicylamid
compound
similar
thiazolid
nitazoxanid
prodrug
activ
compound
tizoxanid
nitazoxanid
shown
broad
spectrum
efficaci
albeit
unknown
mode
action
antiprotozoan
activ
efficaci
influenza
viru
hepat
b
rotaviru
noroviru
phase
ii
clinic
trial
chronic
hepat
combin
therapi
interferon
also
report
inhibit
matur
influenza
viru
hemagglutinin
presum
golgi
apparatu
disrupt
membran
potenti
mycobacterium
tuberculosi
nitazoxanid
pka
also
antivir
efficaci
hepat
c
viru
hcv
presum
activ
protein
kinas
r
pkr
pkr
howev
use
pkrknock
mous
embryo
fibroblast
find
role
pkr
niclosamid
mediat
block
infect
data
shown
nonetheless
niclosamid
inhibit
infect
phdepend
virus
hcv
sar
coronaviru
mechan
inhibit
unknown
show
niclosamid
inhibit
infect
human
rhinovirus
influenza
viru
block
acidif
endolysosom
compart
niclosamid
affect
viral
uptak
cell
sinc
act
post
convers
hrv
upon
receptor
engag
post
endocyt
compart
instead
niclosamid
act
proton
carrier
synerg
inhibitori
effect
vatpas
inhibitor
process
affect
ph
homeostasi
endosom
tightli
maintain
normal
cell
review
mode
action
niclosamid
differ
vatpas
inhibitor
lysosomotrop
agent
ammonium
chlorid
chloroquin
latter
trap
cation
speci
acid
organel
owe
basic
pka
therebi
elev
endosom
ph
specul
lower
appar
toxic
niclosamid
compar
vatpas
inhibitor
could
due
phtune
action
base
mildli
acid
pka
niclosamid
would
differ
bafilomycin
block
rotat
vatpas
subunit
proton
flux
independ
lumin
ph
niclosamid
affect
atp
hydrolysi
purifi
ccv
unlik
requir
lower
micromolar
concentr
antivir
efficaci
lysosomotrop
agent
effect
low
millimolar
concentr
compar
chloroquin
hepat
c
viru
monodansylcadaverin
dengu
viru
unlik
niclosamid
appar
induc
intracellular
vacuol
suggest
accumul
aqueou
lumen
low
ph
compart
support
observ
hydrophob
index
niclosamid
increas
neutral
acid
ph
shown
experiment
data
niclosamid
act
differ
classic
ionophor
nigeracin
exampl
mitochondri
proton
gradient
uncoupl
high
concentr
potassium
ion
k
therebi
catalyz
electroneutr
exchang
k
proton
without
affect
membran
potenti
infect
block
niclosamid
revers
addit
low
ph
medium
suggest
endosom
ph
rather
ph
gradient
across
endosom
membran
crucial
hrv
infect
distinct
valinomycin
disrupt
membran
potenti
shuttl
na
proton
also
unlik
niclosamid
neutral
endosom
ph
inhibit
counterion
influx
sinc
cation
efflux
rather
anion
influx
accompani
endosom
acidif
least
mildli
acid
rang
chemic
properti
niclosamid
make
unlik
act
alkali
ionophor
monensin
form
zwitterion
complex
monoval
cation
transport
membran
interestingli
niclosamid
relat
compound
inhibit
phdepend
virus
also
albeit
moder
less
phdepend
strain
result
good
agreement
infect
inhibit
profil
eipa
ethylisopropylamilorid
inhibitor
sodiumproton
exchang
regul
endosom
ph
exampl
niclosamidesensit
sensit
eipa
niclosamideinsensit
affect
eipa
data
shown
suggest
ionic
milieu
endosom
affect
infect
possibl
control
membran
traffick
homeostasi
support
observ
niclosamid
alter
mildli
acid
earli
endosom
compart
possibl
lumin
ph
control
interact
membran
traffick
regul
csubunit
vatpas
complex
arf
gtpexchang
factor
arno
membran
embed
anchor
atpas
complex
membran
control
proton
transport
show
niclosamid
induc
neutral
endosom
ph
offer
explan
varieti
cell
biolog
effect
attribut
compound
past
niclosamid
safe
use
human
sinc
decad
optim
treatment
gastrointestin
parasit
also
test
anim
model
viral
infect
inhibit
ideal
applic
via
inhal
rout
order
obtain
high
local
concentr
maxim
efficaci
modif
chemic
structur
eg
gener
prodrug
may
prove
use
advanc
potenti
physicochem
interfer
treatment
respiratori
viral
infect
fact
niclosamid
protonophor
independ
protein
target
broadspectrum
antivir
efficaci
enforc
concept
host
target
antivir
therapi
may
spur
develop
novel
direct
protonophor
tune
particular
cellular
compart
virus
cell
essenti
prepar
describ
hela
cervic
carcinoma
cell
strain
ohio
l
kaiser
univers
hospit
geneva
switzerland
primari
human
embryon
lung
cell
american
type
cultur
collect
human
lung
adenocarcinoma
epitheli
cell
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
lglutamin
non
essenti
amino
acid
fetal
bovin
serum
sigma
humidifi
incub
propag
subconflu
twice
week
experi
passag
number
kept
maximum
post
thaw
infect
experi
well
plate
matrix
thermo
scientif
cell
split
day
experi
hrv
serotyp
wm
lee
univers
wisconsin
madison
wi
usa
hrv
l
kaiser
univers
hospit
geneva
switzerland
univers
turku
finland
influenza
strain
puerto
grown
mdck
cell
kind
gift
j
pavlov
univers
switzerland
express
gfp
major
cmv
promot
kind
gift
c
fraefel
univers
genet
natur
hrv
serotyp
use
verifi
diagnost
sequenc
conca
sigmaaldrich
enzo
life
scienc
switzerland
niclosamid
obtain
two
sourc
prestwick
illkirch
franc
sigma
batch
sigma
pure
thin
layer
chromatographi
batch
see
supplier
homepag
certif
analysi
tvbcompound
suppli
bioscienc
menlo
park
ca
usa
origin
screen
librari
fda
approv
compound
prestwick
singl
cell
highcont
imag
base
infect
assay
appli
measur
infect
high
throughput
format
virus
ad
cell
infect
medium
contain
bsa
dmem
contain
mm
hepe
use
outsid
cell
cultur
incub
supplement
lglutamin
mm
bsa
sigma
cv
hrv
infect
medium
contain
trypsintpck
dmem
supplement
lglutamin
tpcktrypsin
sigma
normal
growth
media
hsv
experi
multipl
infect
moi
chosen
approxim
cell
infect
h
post
infect
pi
hrv
cv
h
pi
flu
h
pi
hsv
cell
fix
ad
volum
paraformaldehyd
solut
wash
pb
mm
pb
permeabil
triton
sigma
wash
twice
pb
block
bsa
fraction
v
sigma
antibodi
detect
viral
infect
use
follow
mab
english
scientif
consult
bt
hungari
detect
hrv
cv
infect
mab
detect
flu
nucleoprotein
kind
gift
j
pavlov
univers
switzerland
secondari
reagent
use
alexafluor
label
antibodi
invitrogen
togeth
dapi
stain
nuclei
autom
imag
acquisit
perform
imagexpress
micro
molecular
devic
equip
coolsnap
hq
greyscal
camera
roper
scientif
superfluor
na
superfluor
na
superfluor
na
nikon
object
routin
imag
per
well
acquir
yield
averag
cell
analys
per
well
data
point
imag
overlay
made
use
metaxpress
molecular
devic
imagej
nih
imag
http
rsbwebnihgovnihimag
imag
analyz
use
custom
written
matlab
routin
dose
respons
curv
fit
obtain
prism
softwar
version
graphpad
softwar
inc
use
standard
hill
curv
fit
infect
indic
repres
function
inhibitor
concentr
determin
valu
drug
concentr
drug
provok
respons
half
way
top
respons
infect
assay
maxim
inhibit
respons
use
variabl
slope
model
repres
fourparamet
doserespons
curv
determin
effect
compound
product
infecti
viru
cell
treat
indic
infect
h
progeni
viru
recov
cell
three
freezethaw
cycl
debri
separ
supernat
centrifug
min
titer
supernat
determin
serial
dilut
helaohio
cell
stain
cell
crystal
violet
calcul
valu
accord
spearman
h
infect
sampl
serv
control
input
viru
carryov
compound
dissolv
dimethyl
sulfoxid
dmso
cell
cultur
grade
sigma
ad
cell
dilut
indic
respect
concentr
solvent
alon
control
infect
assay
cell
preincub
compound
min
indic
infect
medium
viru
ad
cell
h
presenc
absenc
compound
cell
fix
immunestain
infect
analys
endosom
trap
virus
ad
cell
infect
medium
intern
h
respect
compound
dilut
infect
medium
ad
equal
volum
min
shift
sampl
h
infect
quantifi
immunestain
dsrna
ph
rescu
virus
trap
h
presenc
compound
medium
replac
buffer
contain
mm
nacl
differ
ph
without
niclosamid
mm
hepesnaoh
ph
mm
morpholineethanesulfon
acid
me
ph
mm
sodium
acet
ph
cell
infect
h
infect
continu
anoth
h
infect
medium
contain
pleconaril
inactiv
nonconvert
virus
capsid
preincub
experi
niclosamid
indic
virus
either
incub
small
volum
niclosamid
infect
medium
without
compound
min
incub
viru
ad
cell
follow
either
addit
infect
medium
niclosamid
reach
respect
concentr
viru
pretreat
sampl
h
infect
cell
fix
immunestain
infect
analys
intracellular
ph
measur
helaohio
cell
seed
imag
compat
well
plate
matrix
thermo
scientif
wash
next
day
pb
incub
compound
dilut
hank
buffer
salt
solut
hbss
invitrogen
min
equal
volum
solut
ao
life
technolog
hoechst
sigma
lysotrack
mm
stock
dmso
life
technolog
ad
medium
incub
min
cell
wash
twice
hbss
immedi
imag
imagexpress
micro
molecular
devic
equip
coolsnap
hq
bit
greyscal
camera
roper
scientif
heat
unit
keep
imag
stage
superfluorna
object
nikon
filter
set
ao
green
excit
nm
emiss
nm
red
excit
nm
emiss
quantif
perform
use
open
sourc
imag
analysi
framework
cellprofil
version
wwwcellprofilerorg
raw
fluoresc
intens
quantifi
perinuclear
area
raw
fluoresc
intens
lysotrack
ratio
green
red
fluoresc
ao
fluoresc
intens
compart
stain
earli
endosom
antigen
rabbit
polyclon
antibodi
novu
biolog
cat
mous
antibodi
santa
cruz
biotechnolog
measur
rel
untreat
cell
ccv
suspend
assay
buffer
mm
hepe
mm
kcl
mm
edta
incub
mm
atp
ao
molecular
probe
atpas
reaction
initi
ad
mm
fluoresc
determin
nm
plate
reader
tecan
switzerland
room
temperatur
min
sampl
without
use
control
cow
brain
ccv
prepar
describ
dilut
assay
buffer
mm
sucros
mm
kcl
mm
hepe
mm
edta
nigericin
oligomycin
mm
vanad
incub
respect
compound
min
atp
mm
atp
mm
ad
sampl
incub
min
product
inorgan
phosphat
pi
measur
sensolyt
mg
phosphat
assay
kit
accord
manufactur
protocol
anaspec
cell
toxic
assess
resazurin
fluorometr
method
brief
steril
filter
resazurin
mgml
stock
solut
pb
sigma
store
protect
light
ad
cell
final
concentr
togeth
compound
interest
incub
incub
indic
convers
resazurin
fluoresc
product
measur
use
plate
reader
tecan
infinit
excit
nm
emiss
nm
wavelength
constant
gain
time
liposom
soy
phosphatidylcholin
prepar
mm
acet
ph
contain
mm
kda
fitcdextran
use
standard
extrus
protocol
yield
vesicl
averag
size
nm
measur
use
particl
size
analyz
nicomp
nicomp
port
richey
fl
usa
nonencapsul
fitcdextran
remov
size
exclus
chromatographi
column
pharmacia
follow
extens
dialysi
mm
acet
ph
floatalyz
kda
cutoff
spectrumlab
measur
fluoresc
dequench
fitcdextran
contain
liposom
dilut
pb
incub
respect
compound
room
temperatur
analys
fluoresc
use
plate
reader
tecan
safir
ii
fluoresc
top
measur
set
excit
nm
emiss
nm
wavelength
within
min
control
measur
sampl
contain
pb
triton
compound
alon
carri
measur
background
maxim
readout
assay
autofluoresc
compound
data
normal
pb
control
background
fluoresc
subtract
cell
pretreat
compound
alon
combin
infect
indic
analyz
use
immunestain
autom
microscopi
describ
macsynergi
ii
use
calcul
synergi
interact
indic
briefli
theoret
addit
interact
calcul
doserespons
curv
individu
drug
calcul
addit
surfac
subtract
experiment
surfac
obtain
synergi
surfac
repres
percentag
inhibit
calcul
addit
valu
peak
plane
suggest
synergi
likewis
peak
plane
indic
antagon
